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Abstract
We present a mathematical model, based on ordinary differential equations, for
the evolution of solid tumors and their response to treatment. Specifically the effects
of a cytotoxic agent and a monoclonal antibody are included as control term in the
equations. The variables considered here are: the number of cancerous cells sensitive to
chemotherapy, the number of cancerous cells resistant to chemotherapy, the degree of
angiogenesis and the average intensity of VEGF. The rules that govern the quantities
mentioned above are based on a geometrical argument: we approximate the tumor
mass as a sphere and thus derive basic formulae for the normoxic cells and for VEGF
production. The monoclonal antibody acts on VEGF and thus has influence to the
global degree of angiogenesis. Numerical estimates on some of the parameters are
performed in order to match the main landmark in tumor progression and reaction to
treatment in the specific case of colorectal cancer.
1 Introduction
Mathematical oncology promises to be a powerful tool to study cancer progression. Dif-
ferential equations models for various quantities, including a spatial structure or not, have
been developed with the specific purpose of analyzing the change in tumor size over time.
In addition, mathematical models are also helpful to understand the long term dynamics
of tumor growth as well as to test biological hypothesis or to evaluate different treatment
options. Various technique for quantitative estimates are applied in order to match quan-
titative values proper of this disease: this is possible after a rigorous calibration of such
models using clinical or experimental data.
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Several mathematical models of tumor growth based on ordinary differential equations
have been proposed in literature. The core of these models is the presence of two equations
for the number of cells and the carrying capacity, that is the level of angiogenesis. The
models can reproduce the main features of tumor growth, see for instance [6], [23], where
tumor growth is gompertzian, or [44], with a modification of gompertzian growth, or [14],
where the tumor growth is logistic. Some of these models based on ODE do not omit
the spatial structure completely: some of them apply a spherical approximation of the
tumor mass (multicellular tumor spheroids) and prescribe a growth rule based on such
approximation, see [33] for an example.
VEGF has already been introduced in previous models: in [18], [27], [39] molecularly
detailed models of VEGF have been studied; [1] and [3] introduce ODEs models involving
the number of cells, angiogenesis and growth factors. In literature several models involving
cytotoxic and antiangiogenic therapies can be found: see [6], where combination between
cytotoxic and antiangiogenic therapies is being optimized, [5], where the cytotoxic and
antiangiogenic drugs are combined with surgery, [32] and [34], again comparing cytotoxic
and antiangiogenic agents, and [2], where a model involving antiangiogenic therapy is
studied. Moreover, models which involve cytotoxic agents impose a complex argument:
birth and evolution of drug resistance cells, widely studied in [11][15][31] [43][48].
Inspired by previous works we aim to formulate a mathematical model that is able
to match the main landmarks in tumor development in the growth phase as well as the
response to specific treatment, with a reasonable level of approximation. Summarizing, the
general aims of this paper are the following: (1) we want to develop a model to reproduce
qualitative aspects of the growth, specifically the transition between the exponential growth
in the beginning and a slower regimen when the number of cells increase, trying to partially
restore the exponential growth after the angiogenesis takes place. (2) We would like to
specialize our model to a concrete case (colorectal cancer) and calibrate the parameters in
order to match quantitative values proper of this disease. (3) Referring to the previous
point, we want to embed in our model a combination therapy in order to compare the
results obtained with those coming from clinical trials. Specifically, we have in mind to
include the action of a cytotoxic agent, directly on the number of cells, as well as the action
of an antiangiogenic agent on the VEGF variable. We also plan to introduce drug-resistant
cells into the system to take into account the deterioration of chemotherapy efficacy.
The paper is organized as follow. The mathematical model is presented in section 2.
Section 3 is entirely devoted to the choices for the parameters, whose calibration was per-
formed in the specific case of colorectal cancer, while in section 4 we present the numerical
results concerning size and TTP (time to progression) in a specific treatment regimen.
Finally in section 5, a brief conclusion is given.
2
2 The mathematical model
The general rationale of our model construction has been to use a very small number
of variables, with a clear biophysical meaning, simple but still preserving general main
mechanisms of cancer growth. We neglect details of the spatial structure and thus do not
consider the position of cancer cells and the space-dependence of VEGF concentration and
vascularization. We consider the following variables:
• N senst = number of drug-sensitive cells;
• N rest = number of drug-resistant cells;
• Vt = intensity of VEGF field (space average);
• At = level of vascularization due to angiogenesis (space average).
For convenience we introduce also the total number of cells:
• Nt = N senst +Nnormt .
In order to include the effect of a cytotoxic agent (5-FU) we divide the population of can-
cerous cells into two subpopulations: here N senst represents the number of cells sensitive
to chemotherapy and N rest the number of drug-resistant cells. Although the complexity of
drug-resistance phenomenon, we assumed for simplicity the resistance as a binary prop-
erty. To describe the dynamic of the two populations we follow the classical approach of
distinguishing the proliferative behavior according to oxygen availability. Thus we divide
each population of cells into two subclasses: normoxic (hence potentially proliferating) and
hypoxic cells, denoted by N i,normt and N
i,hypo
t respectively.
Let us now describe the differential equations satisfied by the previous quantities:
d
dt
N senst = (1− p) · (1− uFUt ) · λN sens,normt − µN senst (1)
d
dt
N rest = p · (1− uFUt ) · λN sens,normt + λN res,normt − µN rest (2)
d
dt
Vt =
Chypo→V
(
Nhypot
Nt
)2/3
− CA,VAt − Cbeva→V ubevat
Vt (1− Vt) (3)
d
dt
At = 1Vt>V0CV→A (Vt − V0) (At +A0) (1−At)− 2AkAt 1Vt≤V0 (4)
where
N i,hypot = (1−At)N it
(
1− 1
1 +
(
N it
)1/3
/2ηi
)3
(5)
and uFUt and u
beva
t describes the tissue concentration of the cytotoxic agent and of the
monoclonal antibody respectively (more details in section 4.2).
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2.1 On the geometrical configuration of the hypoxic and normoxic cells
Let us now introduce the spherical approximation that we have used to describe the variable
fraction of the normoxic (resp. hypoxic) cells over the total number of cells. We assume
that there are two classes of normoxic cells: those near the boundary of the tumor mass,
and those not near the boundary but reached by the new vascular network produced by
the angiogenic cascade. In order to have a simple formula for the boundary of the tumor,
we assume it has a spherical shape - this is true only approximately, for various reasons,
including the complex geometry of real tissues and the rugosity of the surface, but we
cannot include these factors unless we go back to space-dependent models. Let δ be the
thickness of the proliferating boundary and let R and r be the radius of the tumor mass
and of a single tumor cell respectively. By a simple calculation we have
Nnormboundary = N
(
1−
(
1− δ
R
)3)
Let us consider two extreme regimes regarding tumor size. When the tumor is very small,
δ = R. When the tumor is very large, we assume δ stabilizes to a certain number η of cell
diameters, hence δ = 2ηrcell. Therefore
δ
R
=
{
1 when N is small
2η/N1/3 when N is large
.
A simple function which interpolates these two extremes is
δ
R
= f (N, η) =
1
1 +N1/3/2η
.
Thus, we arrive to the formula:
Nnormboundary = N
(
1−
(
1− 1
1 +N1/3/2η
)3)
.
The contribution coming from those cells, in the complementary of the boundary layer,
which are sufficiently angiogenized to be considered as normoxic, is given by
Nnormangio = A ·N
(
1− 1
1 + (N)1/3 /2η
)3
,
where At is the average level of vascularization defined above. The hypoxic cells are simply
obtained by difference.
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2.2 Growth dynamics of sensitive and resistant cells
The reason of deterioration of therapy we take into account is the presence of drug-resistant
mutations. We shall rewrite equation (1) and (2) using vector notation:
d
dt
Nt = λUP
tNnormt − µNt (6)
where
Nt =
(
N senst
N rest
)
, Nnormt =
(
N sens,normt
N res,normt
)
, P =
[
1− p p
0 1
]
, U =
[
1− uFUt 0
0 1
]
.
We simplify and prescribe that each cancer cell, during a duplication, has a probability p
of developing a drug-resistant mutation. The mechanism of mutation is like a change of
species. Following this general rationale we summarized this phenomenon by the transition
matrix P of a Markov chain. A precise rule of growth of the two subpopulations N senst , N
res
t
would be quite intricate and depend on the relative geometry. Indeed, the approximation
of a spherical shape cannot work simultaneously for both, since they are interlaced. Let us
distinguish before and after treatment. Before treatment, N senst >> N
res
t , hence the sphere
approximation for drug-sensitive is reasonable. But drug-resistant cells are distributed,
inside the tumor mass, in a quite complex way. Somewhere we expect to see kernels of
drug-resistant cells due to a first mutated cell together with its descendants; however,
this kernel cannot proliferate indefinitely as the global tumor mass because it is partially
or completely absorbed into the deeper, hypoion. In order to “close” our equations, we
conjecture that the proliferating boundary of the drug-resistant cells is thinner than the case
of sensitive cells. For this reason, and for the sake of simplicity, we use the same spherical
approximation even for the resistant cells but we take ηres < ηsens. After treatment, the
approximation as two separate spheres becomes more reasonable, since mutated kernels
of cells may remain isolated by the loss of surrounding non-mutated cells and, again to
simplify, we assume that the drug-resistant mass is dominated by the largest kernel of
mutated cells, so the approximation as a single sphere is not too distant from reality. In
this case we thus take ηres = ηsens.
We point out that equation (6) contains a small inaccuracy: during treatment sensitive
cells are affected by chemotherapy while resistant cells are not. In this phase the control
term 1−uFUt is negative and causes a decrease in the number of sensitive cells: this decrease
is slightly altered due to the fact that N sens,normt is scaled by the term (1−p) coming from
the matrix P . In practise this inaccuracy will be numerically negligible given that average
values of p will range from 10−6 to 10−4 and thus (1− p) ∼ 1.
2.3 The 2/3 formula for VEGF and the angiogenesis (de)generation
The VEGF field is produced by hypoxic cells and absorbed by endothelial cells. The factor
Vt (1− Vt) in equation (3) has the role to restrict Vt in (0, 1), where the choice of 1 as
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maximal value of Vt is conventional. The term −CA,VAt is the natural one to describe
absorption by endothelial cells - moreover, it will play a very marginal role in the sequel.
The 2/3 rule for VEGF production by hypoxic cells is justified by the argument that
follows. Consider the sphere of hypoxic cells as it were a uniformly “charged” sphere of
radius R− δ: it induces the electric field
E(r) =
C (R− δ)3
r2
,
for a suitable constant C. The potential on the boundary of the sphere is
V (R) = C (R− δ)2 .
This is the work done by the electric field to move a point charge from infinity to the
boundary of the sphere. In analogy, we think to VEGF as the work needed to move blood
vessels from an infinite distance to the sphere of hypoxic cells. Thus VEGF would have
the form
Vt = C (Rt − δt)2 = C˜(Nhypot )2/3
with a new constant C˜.
The equation (4) describes the growth of vasculature by the term
1Vt>V0CV→A (Vt − V0) (At +A0) (1−At) ,
while the second term
−2AkAt 1Vt≤V0
concerns the regression due to monoclonal antibody. The bio-mechanical rule of regression
is different from the one of accretion. Indeed, when regression occurs, the more recent
capillaries are still poor in structure - e.g. not so covered by pericytes - and are easily
destroyed, in a short time (of the order of a week) compared with the long times of the
overall process (of the order of many years). On the contrary, the less recent angiogenic
vasculature has already reached a certain level of stability and thus it regresses much slowly.
We have devised, with some degree of approximation and of ad-hoc numerical trials, the
above law for the regression.
The term A0 has been added because for values of At very close to zero - even equal to
zero - the growth ddtAt is not infinitesimal, but finite non zero, due to the presence of the
pre-existing vasculature.
The term V0 corresponds to the fact that angiogenesis requires some degree of con-
centration of VEGF. Below such threshold no angiogenesis occurs; or more precisely, a
regression takes place.
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Parameters Meaning Value Source
λ growth rate due to cell proliferation 0.05 [8][17][43][49]
µ decay rate due to cell loss 0.002 [8][17][43][49]
ηsens thickness of proliferating boundary of
drug-sensitive cells
15 [50]
ηres thickness of proliferating boundary of
drug-resistant cells
ηsens
1.2 estimated/simulations
Chypo→V VEGF production rate from hypoxic cells 0.08 estimated/simulations
CA,V absorption rate of VEGF from vasculature 0.01 estimated/simulations
CV→A reaction rate of angiogenesis to VEGF 0.006 estimated/simulations
A0 preexistence level of vascularization 0.2 estimated/simulations
kA angiogenesis regression rate 10 estimated/simulations
V0 VEGF threshold for angiogenesis progres-
sion
0.2 estimated/simulations
p probability of drug resistant mutation per
cell per duplication
10−5 [11][15][31] [43][48]
Nstart number of cells when therapy starts 10
9 [35][51]
NFU number of days of action of 5-FU (1 to 7) 6 [41]
CFU intensity of 5-FU action 20 estimated/simulations
Nbeva number of days of action of BV5 (1 to 14) 12 [20][37]
Cbeva→V inhibition rate of bevacizumab on VEGF 1 estimated/simulations
Table 1: Parameters of the model. Parameters with no source have been estimated indirectly, refer
to section 4.2.
3 Parameters
This section specializes our model to the case of colorectal cancer. As one can appreciate
from table 1, some values of parameters are available in literature while others, harder to
measure, are estimated experimentally. The first class will be discussed here, while the
others are argued in section 4.2.
We based our approximation of (λ, µ) on the estimate of doubling time of colorectal
cancer. From the literature (see for instance [17] [8], [43], [49]) DT of the order of 60-180
days seems possible (also less and more). Some authors (see [45], [7]) claim that periods
of the order of 8 years could be reasonable estimates of the time needed to reach 109 cells
and this result is not incompatible with the previous estimates of DT, up to some degree of
approximation. We have chosen to impose roughly 8 years to our model to reach 109 cells
and we have computed an average DT of the order of 100 days, where by average we mean
that we take into account the changes of speed of growth that our model has, we compute
at every time the instantaneous doubling time and we average it (fig. 1). Obviously there
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Figure 1: Istantaneous doubling time (DT) as it varies over the whole period. The average is 107,
coherent with the literature.
are several choices of parameters which produce these results. We choose as a standard
the values in table 1.
The number of cells when therapy starts is obtained by translating available statistics
about the volume which around tumors become detectable (∼ 1cm3), see for instance [35]
[51].
For what concerns the thickness of proliferating boundary ηsens, we obtain the range
5 − 30 through two different arguments. The first one is given by experimental estimates
about the distance from a capillary at which cells start to be hypoxic or even necrotic; see
a collection of results in [50], figure 13.27 and references therein. These estimates range
between 60 and 110 µm, namely less than 10 cells. However, the external proliferating layer
is exposed to a much richer amount of oxygen and nutrients than a packed tumor around
a capillary. Thus, the previous estimates should be corrected in the increasing direction.
Another argument comes from the observation that tumors with radius of size around
1mm are usually avascular, hence for them the proportion α of proliferating boundary
with respect to the total is not small. Let us see that values of α of the order 0.25, 0.50,
0.74 give rise to estimates of ηsens again of the order of 10. We assume as above that the
cell radius is 6µm = 6 ·10−3mm. Similarly to the computation of the section 2.1 we assume
to have a spherical tumor of radius R and an external proliferating layer of thickness δ;
hence, in mm, δ = 2 · 6 · 10−3ηsens. We want to estimate δ, and therefore ηsens = 103δ/12.
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Figure 2: Size of η as a function of α, see text.
The number α is the ratio between the two volumes, hence
α =
R3 − (R− δ)3
R3
= 1− (1− δ)3
where we have used R = 1. Hence
ηsens =
103
(
1− 3√1− α)
12
.
We see from figure 2 that reasonable values are around 10-30; mixing with [50] we choose
η = 15.
The value of p is a very delicate issue, see [15]: it derives from the assumption that the
mechanism of mutation is a binary random variable. Our reference value has been 10−5
and the range under randomization has been between 10−4 and 10−6: we obtained this
values by numerical simulations comparing our results with the clinical about TTP found
in [29], more details in section 4.2. In support of these values let us quote for instance [48],
[21] (page 3650), [31] (section 5.3), [11]. The long time between cell divisions of colorectal
cancer cells may be a factor of increase of p, see [19].
The parametersNFU , CFU , Nbeva, Cbeva→V are included in the control functions uFUt , ubevat .
Concerning 5-FU, its half-life in plasma is very short, of the order of 10-20 minutes, but
in tissues occupied by cancer cells appreciable levels are measured for days, see [41] (in
particular figure 1). Concerning BV5, it seems it remains active for a long period, see for
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Figure 3: Sensitivity analysis: parameters changed vs percentage change in tumor size after 8
years of growth. Parameters are changed of 50% from table 1, except p, which is altered from 10−6
to 10−4.
instance [20][37], thus we take Nbeva = 12. The study of parameters, whose values are not
known in literature, represents one of the most difficult point of our work: the idea was
to search for the range of admissible values through numerical simulations. Fixing some
constraints we have studied the reasonable value of parameters. As largely explained in the
following section, we have in mind two kind of constraints: the first class consists of uni-
versal characteristics of tumor evolution while the second consists of specifics of colorectal
cancer.
4 Numerical Simulations
In this section we propose two different approaches to investigate and validate the model.
In the first section we show the biological events caught by our model, while in the second,
focused on therapy, we try to compare our result with clinical data proposed in [29].
4.1 General shape of growth
By observing figure 5 we can appreciate the general shape of the growth curve over a large
time interval (roughly ten years). When the tumor is small we have Nnormboundary ∼ N , hence
in the first segment of the curve the growth is purely exponential. When the tumor is
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Figure 4: Sensitivity analysis: parameters changed vs percentage change in TTP after treatment
(see section 4.2). Parameters are changed of 50% from table 1, except p and Nstart, which are
altered from 10−6 to 10−4 and from 108 to 1010 respectively.
larger, namely when N1/3/η  1, we have
Nnormlayer ∼ N
(
1−
(
1− 2η
N1/3
)3)
∼ 3N 2η
N1/3
= 6ηN2/3.
The 2/3 law often appears in the literature, see for instance [46] and the references therein.
Later on, thanks to the angiogenic contribution, we restore the exponential growth rate:
in fact when N is large
N
(
1− 1
1 +N1/3/η
)3
∼ N.
Comparing the solution of the system (1)-(4) with a classical Gompertz model, charac-
terized by only two phases, it is possible to distinguish a third phase where the exponential
rate is restored by angiogenesis.
Keeping in mind the focus on colorectal cancer, we direct our attention to the numerical
values proper of this disease:
• roughly 8 years to reach 109 cells ∼ 1cm3;
• angiogenesis starting between 106 and 2 · 106.
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Figure 5: Simulation without therapy. Diamonds denote the range 106−2 · 106 where angiogen-
esis is expected to start and the first red star is that initial time. The second red star is
when 109 cells are reached which should be close to 8 years. Blue line denotes total number
of cancer cells, green line those having a drug resistant mutation. Concerning parameters,
their value for this simulation is given in table 1 of sections 3.
The first landmark of 1cm3 has already been argued in section 3. Concerning the starting
of the angiogenic cascade, 1mm3 is a typical order of magnitude of the largest avascu-
lar tumors. Around 1 − 2 mm3 the angiogenic cascade starts, see [36]. This translates
to the range 106 − 2 · 106. With these values in mind we have chosen the parameters
Chypo→V , CA,V , CV→A, A0 in order to reproduce these specific events. Obviously there are
several choices of parameters which produce these results (see figure 5). We choose as
standard the values in table 1. To deepen how the just mentioned parameters influence
the model, we propose the analysis of sensitivity in figure 3. From this analysis one can
appreciate the fact that, increasing (resp. decreasing) of 50% parameters which calibrate
rate of angiogenesis development (Chypo→V , CV→A), implies a relevant increase (resp. de-
crease) of tumor size. The same linear effect arises from the parameters that influence the
rate of proliferation for sensitive and resistant cells (ηsens, ηres). Given the strict correla-
tion between (λ, µ) they have not been tested in this phase. In conclusion, the shape of
growth curve seems to be very stable with respect to parameters: their alteration entails
the maintenance of the three phases, above mentioned.
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Figure 6: Simulation with therapy, 5-FU plus BV5. Circles denote times of assessment of tu-
mor size. Small subgraphs show the behavior of total number of cells, hypoxic cells, degree of
angiogenesis and density of VEGF.
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4.2 Connections with clinical data
In this section, we follow a second type of validation mechanism for the model: we adapt the
model to a specific case and we try to compare the results obtained through simulations
with those found in literature. In clinical trials, when tumor progression takes place,
the first line therapy is interrupted and patients could receive any second line treatment,
which however may vary and be thus less suitable for a mathematical modeling. Hence,
we limit ourselves to a model of the 5-FU or 5-FU + BV5 regimen during the first-line
therapy and we measure TTP. Our model is not able to capture the spatial structure of
the tumor, so we limit our measurement of TTP on a single lesion of the colorectal cancer.
According to [29] and RECIST criteria, we start from time t0 when therapy begins and
register the number of cells every 8 weeks, namely at the end of each cycle; hence, using the
spherical approximation, we convert number of cells into lesion diameter and we compute
the first measurement with an increase of at least 20 percent from the minimum registered.
Following [29], we investigate the case when patients are initially treated by 12 cycles of 5-
FU (plus folinic acid), each cycle being of 8 weeks with 5-FU administrated at the beginning
of each one of the first 6 weeks of a cycle. We compare this regimen with the one based on
5-FU (and folinic acid) plus bevacizumab. This monoclonal antibody is given once every
two weeks - also the last two weeks of the cycle. The particular regimen bevacizumab 5
mg/kg every 2 weeks will be denoted by BV5 and we refer only to it when experimental
data are quoted. We remind that uFUt and u
beva
t denote the control functions corresponding
to 5-FU and bevacizumab respectively, functions which are equal to zero when 5-FU and
BV5 are not present in the tissue. To be precise, they describe the concentration of 5-FU
and BV5 in the tumor tissue. Two possible misunderstandings should be avoided: i) the
controls uFUt and u
beva
t are not understood as the actions of drug administration, which are
short in time like in the case of 5-FU in bolus; ii) they correspond to drug concentration in
the tumor tissue, not in plasma. We prescribe that the first administration of 5-FU (+BV5)
takes place when the total number of cells reaches the value of Nstart. Concerning 5-FU,
we keep into account two facts: i) cell kill by chemotherapy is faster than proliferation; ii)
the concentration of 5-FU in the tissue decays exponentially in time. Using the following
expression:
uFUt = (1 + CFU ) exp
(
− log (1 + CFU )
NFU
t
)
.
we obtain that at the beginning of the week, when 5-FU is given in bolus, the rate is equal
to
λ
(
1− uFU0
)
= λCFU .
Hence the constant CFU acts as a multiplier of intensity of cell kill with respect to cell
proliferation. A typical value we use is CFU = 20. The expression inside the exponential
has the following motivation: at time t = NFU , we have u
FU
t = 1, hence the rate at that
time is λ
(
1− uFUNFU
)
= 0. In other words, prescribing the number NFU of days of action
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of 5-FU, we prescribe that cell loss occurs until time NFU , in an exponentially decreasing
manner; and afterwords proliferation restarts but not immediately with full rate λ, just
with rate λ
(
1− uFUt
)
which is asymptotic to λ for large times.
Concerning bevacizumab, it is given once every two weeks in each cycle. In the periods
of no treatment, ubevat = 0. Under treatment, we impose that its half-life is NBV , hence
the form is
ubevat = exp
(
− log 2
NBV
t
)
.
In figure 6 it is shown the simulation of the therapy, including bevacizumab. Two of nine
parameters whose values are not available in literature are included in the control func-
tions, namely CFU , Cbeva→V . In figure 7 it is shown the time segment where the therapy
is active. According to clinical results shown in [29], our model catches the relevant signif-
icance of addition of BV5 to the therapy: in this case TTP is increased from 7.5 months
to 9.3 months (in [29] PFS increases from 7.3 to 9.2). As explained in section 3, some of
the parameters whose values are missing, are estimated in a indirect way: we estimated
these parameters, in order to obtain reasonable results of TTP (see fig 4 pag. in [29]) and
maintaining at the same time the biological constraints described in the previous section.
In figure 4 we can appreciate how parameters influences effectiveness of the therapies. The
rate of angiogenesis regression, as well as the reaction rate of angiogenesis to VEGF, af-
fects inversely the efficacy of therapy, in particular of bevacizumab. Moreover parameters
linked to chemoresistant cells, ηres, p, act inversely on TTP, while the thickness of prolif-
erating boundary acts proportionally, according to the fact that chemotherapy kills only
proliferating cells. Although altering (λ, µ) will break the specific constraints imposed in
subsection 4.1, we include them into the analysis of sensitivity in order to show how growth
rate influences TTP.
5 Conclusion
We have devised a mathematical model that governs cancer growth, specifically in the case
of solid tumors, and includes the action of a cytotoxic agent and of a monoclonal antibody
as control terms. The equations considered here have been proved to be suitable to the
case of colorectal cancer. Further investigation is required to claim their applicability to
other kind of solid tumors, provided that the spherical approximation is reasonable. The
action of the control functions could be used in a variety of contest where the effect of such
treatment is required, but again, this will require additional effort to be established.
The model is formulated as a system of ordinary differential equations that describe
the total number of cells, both sensible and resistant to the cytotoxic agent, the intensity
of VEGF field and the level of vascularization due to angiogenesis. As expressed in the
introduction the choice of VEGF as one of the variables was mainly due to our desire to
include bevacizumab into the system. Even if the equations are ODEs we have taken into
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Figure 7: Zoom around treatment section. The first figure show the treatment with only 5-FU
while the second with 5-FU plus BV5. Orange circles denote time of assessment of tumor size, the
bigger square represents the nadir point and the two black diamonds denote the limits for TTP.
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account the spatial structure through equations (1), (3), (5): the rule used here for the
number of proliferating cells in absence of angiogenesis, namely Nnormboundary, is a variant of
Verhulst model, which has the form Nt
(
1− (NtK )α). We have devised this formula, based
on geometrical considerations, to take into account the transition between an exponential
growth and a slower growth when the number of cancerous cells is substantial. The 2/3
formula for VEGF was obtained from more physical argument, once more using the hy-
pothesis of spherical symmetry. Due to the structure of the equations and their interaction
we were able to obtain a curve of growth that results in a proper asymptotic rate in every
phase of tumor development (figure 5).
Numerical simulations were used both as a validation mechanism for the model and
as a way to obtain an estimate for some of the parameters. In order to extract more
information from the simulations, comparison with clinical data was also performed: we
focused on the specific case of colorectal cancer and measure TTP following the treatment
prescribed in [29]. In this case we use TTP as an output to obtain additional informations
on the parameters involved in the therapy.
The sets of parameters shown in table 1 is able to match all the quantitative key
landmarks imposed in section 4.1, as well as TTP in both regimen 5FU and 5FU+BV5.
In a subsequent work we shall investigate the modifications played by the explicit
introduction of metastases, their growth, size at the time when therapy starts, impact on
TTP computation. Another generalization we have in mind, which moreover has been
the initial motivation of our study, is to investigate more complex therapies, as those
summarized in [12]. We have preferred to isolate the simplest case here because it may be
modified to treat other types of cancer, due to its simplicity.
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